GlaxoSmithKline

GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the following segments: Pharmaceuticals; Pharmaceuticals R&D; Vaccines and Consumer Healthcare. The Pharmaceuticals segment focuses on developing medicines in respiratory and infectious diseases, oncology, and immuno-inflammation. The Pharmaceuticals R&D segment focuses on science related to the immune system, the use of human genetics and advanced technologies, and is driven by the multiplier effect of Science x Technology x Culture. The Vaccines segment produces pediatric and adult vaccines to prevent a range of infectious diseases including, hepatitis A and B, diphtheria, tetanus and whooping cough, measles, mumps and rubella, polio, typhoid, influenza, and bacterial meningitis. The Consumer Healthcare segment develops and markets brands in the oral health, pain relief, respiratory, nutrition and gastro intestinal, and skin health categories. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.

Vertex Pharmaceuticals

Investors interested in Medical - Biomedical and Genetics stocks are likely familiar with GSK (GSK) and Vertex Pharmaceuticals (VRTX). But which of these two stocks presents investors with the better value opportunity right now?

GSK vs. VRTX: Which Stock Is the Better Value Option?

The World Health Organization said on Tuesday that data shows resistance to the drug is growing in patients receiving GSK's HIV drug, dolutegravir.

WHO says resistance to GSK's HIV drug is growing

GSK said on Monday a new formulation of its HIV prevention and treatment drug could potentially be administered at least every four months, an improvement from the previous requirement of dosing every two months.

GSK's new HIV drug formula could support longer dosing intervals

Glaxo (GSK) reported earnings 30 days ago. What's next for the stock?

Glaxo (GSK) Up 3.1% Since Last Earnings Report: Can It Continue?

GSK PLC (LSE:GSK, NYSE:GSK) boss Emma Walmsley saw her overall pay rise 51% to around £13 million in 2023 after she received a large hike in performance-related bonuses. Some £11 million of the pay came from performance bonuses and awards after the pharma giant beat estimates in the fourth quarter of 2023 - the first full financial year since it spun off Haleon.

GSK boss sees pay jump 51% in 2023

GSK CEO Emma Walmsley's total remuneration rose 51% to 12.7 million pounds ($16 million) in 2023, thanks to a big jump in performance-related pay, the British drugmaker's annual report showed on Friday.

GSK CEO Emma Walmsley's total pay rises 51% to nearly 13 mln pounds in 2023

In the most recent trading session, GSK (GSK) closed at $41.90, indicating a -1.04% shift from the previous trading day.

GSK (GSK) Stock Declines While Market Improves: Some Information for Investors

Apple

Amazon

ASML Hld

AstraZeneca

Alphabet

L'Oreal SA

LVMH Moet Hennessy Louis Vuitton

Microsoft

Netflix

Nestle SA

NVIDIA

Novo Nordisk

Novartis

Roche Holding AG

SAP SE

Sanofi

Tesla

Wall Street loves a good story, as evidenced by the recent focus on a group of stocks called the “GRANOLAS.” These are a group of 11 European stocks that have led Europe's stock markets higher.

‘GRANOLAS' vs. the Magnificent Seven: Which should you dig into now?

Zacks.com users have recently been watching Glaxo (GSK) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Investors Heavily Search GSK PLC Sponsored ADR (GSK): Here is What You Need to Know

GSK PLC (LSE:GSK, NYSE:GSK) has confidentially settled a lawsuit in California that claimed its now-discontinued heartburn medication, Zantac, caused cancer. This agreement, ahead of a trial scheduled for April 2, is one of a series as the UK drugs giant attempts to head off expensive and time-consuming litigation.

GSK settles another California lawsuit

GSK agreed to confidentially settle another lawsuit in California that had alleged its discontinued heartburn drug Zantac caused cancer, the latest in a series of settlements made by the British drugmaker to end costly litigation.

GSK settles another lawsuit on heartburn drug Zantac in California

Glaxo (GSK) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

All You Need to Know About Glaxo (GSK) Rating Upgrade to Buy

GSK has hailed the results from a late-stage trial of a new oral antibiotic for gonorrhoea, which met its primary endpoint of at last matching the current standard treatments. Chris Corsico, senior vice president, development, at GSK, said: “With rising incidence rates and concern around growing resistance to existing treatments, gonorrhoea poses a threat to public health globally.

GSK meets main endpoint in oral gonorrhea treatment trial

Here is how GSK (GSK) and Akero Therapeutics, Inc. (AKRO) have performed compared to their sector so far this year.

Are Medical Stocks Lagging GSK PLC Sponsored ADR (GSK) This Year?

British drugmaker GSK said on Monday its oral gonorrhoea drug met its primary goal of non-inferiority in a late-stage trial, compared to an existing combination treatment.

GSK's gonorrhoea drug meets primary goal in late-stage trial

There is a different breed of stocks that investors should be aware of. They are GRANOLAS stocks which can be loosely thought of as the Magnificent Seven, but for European stocks.

Move Over Magnificent 7, Say Hello to the GRANOLAS

NextEra Energy

Target

Good dividend stocks provide their owners with reliable income. What's more, even if these equities drop, investors are “paid to wait” for them to rebound down the road.

3 Low-Priced Dividend Stocks With Solid Fundamentals & Growth

British pharma giant GSK on Wednesday announced promising results for a long-acting injectable HIV therapy, offering a hopeful alternative for people who take daily pills to halt the virus's progression.

First Long-Acting Injectable HIV Treatment Works Better Than Daily Pills For Some Patients, GSK Says

British drugmaker GSK said on Wednesday its long-acting injectable HIV therapy showed promise in keeping the viral load suppressed compared to daily oral treatment, especially in individuals facing challenges with pill intake.

GSK's injectable HIV drug shows promise over daily pills

Cardinal Health

Chubb

Illinois Tool Works

Johnson Controls

Kimberly-Clark

Leggett & Platt

Mondelez

Altria

PepsiCo

Philip Morris

The markets may swing wildly from week to week and month to month, but dividends are seemingly more stable, reliable and predictable.

DivHut Dividend Income Update: January 2024

GSK PLC (LSE:GSK, NYSE:GSK) has announced the US$1.4 billion acquisition of respiratory biopharmaceuticals firm Aiolos Bio. FTSE 100-listed GSK said the takeover, which will se US$1 billion paid upfront followed by a further US$400 million in performance-linked payments, would offer it access to Aiolos' long-acting anti-thymic stromal lymphopoietin (TSLP) treatment.

GSK acquires respiratory firm Aiolos Bio for US$1.4 billion

GSK plc is a multinational “big pharma” and long-time leader in the vaccine, HIV, and respiratory disease areas. Shingrix and RSV vaccine sales in 2023 exceeded expectations and appear to show no sign of slowing down. GSK's franchise only faces minor patent cliffs over the next 5-10 years, supporting its long-term growth plan.

GSK plc: An Undervalued Vaccine Behemoth That Is Resuming Growth; Buy

GSK said on Thursday it had completed the acquisition of Aiolos Bio, a clinical-stage biopharmaceutical company focused on respiratory and inflammatory conditions.

GSK completes acquisition of Aiolos Bio for up to $1.4 bln

SAN DIEGO--(BUSINESS WIRE)--GSK Exercises Option to License Elsie Biotechnologies' Discovery Platform to Find and Develop Novel Oligonucleotides.

GSK Exercises Option to License Elsie Biotechnologies' Discovery Platform to Find and Develop Novel Oligonucleotides

Liberty Global Ltd

A hedge fund has bought a 5% stake in the U.K.'s largest commercial television broadcaster ITV, as the broadcaster struggles against a slump in the advertising market that has pummeled its share price in recent years.

Hedge fund snaps up stake in Love Island maker ITV

News for GlaxoSmithKline Stock (GSK)